Medtronic has presented results from a clinical trial which showed that the remote monitoring of implantable cardiac device patients with the company’s CareLink Network with automatic Medtronic CareAlert Notifications reduces healthcare utilization costs compared to standard in-office follow-up.
The key findings of the Connect (Clinical Evaluation of Remote Notification to Reduce Time to Clinical Decision) trial show that remote monitoring reduces the time from a clinically-actionable event to a clinical decision by 79% (p<0.001), reduces average length of hospital stay for cardiovascular reasons by 18% (0.7 days), and provides estimated costs savings of $1,793 per admission.
The Connect trial also showed a decrease in the number of in-office visits by 38% for patients using the CareLink Network.
Medtronic Cardiac Rhythm Disease Management business senior vice president Pat Mackin said their CareLink Network is a vital, clinically validated patient management tool that is associated with numerous benefits, as demonstrated in the Connect trial.
"We are fully committed to providing patients and physicians with superior cardiovascular management tools that help treat an array of debilitating heart rhythm conditions, as well as help remove costs from the healthcare system," Mackin said.